Eli Lilly partners with OpenAI to use AI in creating new antibiotics for drug-resistant pathogens.
Eli Lilly partners with OpenAI to use generative AI in fighting drug-resistant pathogens, addressing antimicrobial resistance (AMR). The collaboration follows Lilly's $100m commitment to the AMR Action Fund, aiming to create 2-4 new antibiotics by 2030. This partnership leverages AI technology in drug discovery and innovation, supporting public health efforts against antibiotic-resistant bacteria.
June 25, 2024
5 Articles
